Immunoglobulin Or Antibody Is Chimeric, Mutated, Or A Recombined Hybrid (e.g., Bifunctional, Bispecific, Rodent-human Chimeric, Single Chain, Rfv, Immunoglobuin Fusion Protein, Etc.) Patents (Class 435/328)
-
Patent number: 8389691Abstract: This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing endosialin and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to endosialin-expressing cells as well as in eliciting an immune-effector activity particularly on tumor and neovascular cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer and neovascular cells; and methods of treating cancer and neovascular disease using the antibodies, derivatives and fragments.Type: GrantFiled: September 30, 2009Date of Patent: March 5, 2013Assignee: Morphotek, Inc.Inventors: Nicholas C. Nicolaides, Luigi Grasso, Philip M. Sass
-
Patent number: 8388959Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.Type: GrantFiled: December 18, 2009Date of Patent: March 5, 2013Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, David Gailani
-
Publication number: 20130052135Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: ApplicationFiled: October 24, 2012Publication date: February 28, 2013Applicants: Board of Regents, The University of Texas System, MedImmune, LLCInventors: MedImmune, LLC, Board of Regents, The University of Texas System
-
Publication number: 20130052192Abstract: The current invention relates to a construct, a polynucleotide that encodes said construct and a cell that expresses said construct. Furthermore, the current invention relates to the use of said construct for the treatment of bleedings and their associated co-morbidities and to a method of treatment of bleedings, inflammation and metastasis of cancer cells.Type: ApplicationFiled: February 18, 2011Publication date: February 28, 2013Applicant: Novo Nordisk A/SInventors: Jais Rose Bjelke, Susanne Nedergaard Grell, Thomas Egebjerg
-
Publication number: 20130052191Abstract: The invention relates to antibodies directed to ?2?1 integrin and their uses, including humanized anti-alpha 2 (?2) integrin antibodies and methods of treatment with anti-?2integrin antibodies. More specifically the present invention relates to humanized anti-?2 integrin antibodies comprising a heavy chain variable region, a light chain variable region, a human light chain constant region and a variant human IgG1 heavy chain constant region which exhibit altered effector function.Type: ApplicationFiled: February 22, 2011Publication date: February 28, 2013Applicant: SANOFIInventors: Stanislas Blein, Samuel Hou, Darko Skegro
-
Patent number: 8383801Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.Type: GrantFiled: November 19, 2010Date of Patent: February 26, 2013Assignee: Amgen Inc.Inventor: Christopher J. Paszty
-
Publication number: 20130042331Abstract: The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.Type: ApplicationFiled: March 9, 2012Publication date: February 14, 2013Applicant: Kymab LimitedInventors: Allan Bradley, E-Chiang Lee, Qi Liang, Wei Wang, Anais Legent, Ian Kirby
-
Patent number: 8372640Abstract: The invention provides a method for stimulating an immune response by administering to a lymphoid tissue a nucleic acid molecule comprising an expression element operationally linked to a nucleic acid sequence encoding one or more heterologous epitopes. The heterologous epitope can be inserted into a complementarity-determining region of an immunoglobulin molecule. The invention also provides a nucleic acid molecule comprising a hematopoietic expression element operationally linked to a nucleic acid sequence encoding a heterologous polypeptide. The invention additionally provides a method of treating a condition by administering a nucleic acid molecule comprising a hematopoietic cell expression element operationally linked to a nucleic acid sequence encoding a heterologous polypeptide, wherein the nucleic acid molecule is targeted to a hematopoietic cell.Type: GrantFiled: December 18, 2006Date of Patent: February 12, 2013Assignee: Nevagen LLCInventor: Maurizio Zanetti
-
Publication number: 20130034551Abstract: The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and Ror receptors and their use.Type: ApplicationFiled: January 12, 2011Publication date: February 7, 2013Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Sanjeev SATYAL, Satyajit MITRA, Austin GURNEY
-
Publication number: 20130034559Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed.Type: ApplicationFiled: November 24, 2010Publication date: February 7, 2013Applicant: Medlmmune LimitedInventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcook, Ian Nevin Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Stewart, Kathleen Ann Mulgrew
-
Publication number: 20130031647Abstract: The present invention relates to a novel isolated humanized antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. More particularly, the present invention relates to hz515H7 antibodies, specific to the CXCR4 protein, as well as their use for the treatment of cancer. Pharmaceutical compositions composed of such antibodies and a process for the selection of such antibodies are also covered.Type: ApplicationFiled: March 30, 2011Publication date: January 31, 2013Inventors: Christine Klinguer-Hamour, Alexandra Jouhanneaud, Véronique Grenier-Caussanel
-
Patent number: 8361793Abstract: Monoclonal antibodies against gonadotropin releasing hormone (GnRH) receptor induce cellular apoptosis of various cancer cells expressing this surface receptor. The monoclonal antibodies and their humanized forms, or fragments thereof, can serve as anti-cancer agents for the treatment of cancer in humans, and can function as analogs of GnRH to affect regulation of reproductive functions or fertility in humans.Type: GrantFiled: April 13, 2012Date of Patent: January 29, 2013Assignee: Vancouver Biotech Ltd.Inventor: Chi-Yu Gregory Lee
-
Publication number: 20130022595Abstract: The present invention relates to humanized monoclonal antibodies, pharmaceutical compositions that include the same, and use thereof for the treatment of a variety of indications, particularly cancer and immunodeficiency disorders. In particular, the present invention provides modified antibodies or fragments thereof having specific amino acid modifications compared to the humanized monoclonal immunomodulatory antibody termed hBAT-1.Type: ApplicationFiled: July 23, 2012Publication date: January 24, 2013Applicant: CURETECH LTD.Inventors: Rinat Rotem-Yehudar, Michael Schickler
-
Publication number: 20130018174Abstract: The present invention provides efficient methods based on alteration of the protein A-binding ability, for producing or purifying multispecific antibodies having the activity of binding to two or more types of antigens to high purity through a protein A-based purification step alone. The methods of the present invention for producing or purifying multispecific antibodies which feature altering amino acid residues of antibody heavy chain constant region and/or variable region. Multispecific antibodies with an altered protein A-binding ability, which exhibit plasma retention comparable or longer than that of human IgG1, can be efficiently prepared in high purity by introducing amino acid alterations of the present invention into antibodies.Type: ApplicationFiled: December 24, 2010Publication date: January 17, 2013Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuya Wakabayashi, Eriko Ito
-
Publication number: 20130018175Abstract: The present invention relates to immunoglobulin single variable domain sequences that are directed against (as de-fined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.Type: ApplicationFiled: December 14, 2010Publication date: January 17, 2013Applicant: ABLYNX N.V.Inventors: Frank Verdonck, Sigrid Cornelis, Stephanie Staelens
-
Publication number: 20130011401Abstract: The present invention relates to soluble SIRP? binding proteins, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble SIRP? binding protein comprising a complex of two heterodimers, wherein each heterodimer essentially consists of: (i) a first monovalent single chain polypeptide comprising a first SIRP? binding domain fused at the N-terminal part of a heavy chain constant region of an antibody; and, (ii) a second monovalent single chain polypeptide comprising a second SIR % binding domain fused at the N-terminal part of a CL light chain constant region of an antibody. The invention further relates to soluble SIRP-binding antibody-like protein as shown in FIG. 1.Type: ApplicationFiled: December 21, 2010Publication date: January 10, 2013Applicant: NOVARTIS AGInventors: Thomas Huber, Frank Kolbinger, Marie Sarfati, Karl Welzenbach
-
Publication number: 20130011394Abstract: The invention comprises a complex comprising as first part an antibody derived part that specifically binds to a target antigen, and as second part a virus-derived peptide linked to a MHC class I protein complex.Type: ApplicationFiled: June 19, 2012Publication date: January 10, 2013Applicant: Hoffmann-La Roche Inc.Inventor: Hendrik Knoetgen
-
Publication number: 20130005949Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: March 3, 2011Publication date: January 3, 2013Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber
-
Publication number: 20120328513Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.Type: ApplicationFiled: June 20, 2012Publication date: December 27, 2012Applicant: Abbott Biotherapeutics Corp.Inventors: Debbie Law, Kurt Gish
-
Publication number: 20120329997Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: March 3, 2011Publication date: December 27, 2012Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber
-
Publication number: 20120328612Abstract: The present invention relates to anti-FLT3 antibodies with a modified Fc region comprising the amino acid substitutions 239D and 332E to enhance antibody-dependent cell cytotoxicity (ADCC) of these antibodies. The invention further relates to pharmaceutical compositions containing these antibodies, nucleic acids encoding these antibodies as well as methods of using such antibodies.Type: ApplicationFiled: December 23, 2010Publication date: December 27, 2012Inventors: Ludger Grosse-Hovest, Hans-Joerg Buehring, Martin Hofmann, Steffen Aulwurm, Grundram Jung
-
Patent number: 8337853Abstract: The present invention relates to monoclonal antibodies that bind or neutralize dengue type 1, 2, 3, and/or 4 virus. The invention provides such antibodies, fragments of such antibodies retaining dengue virus-binding ability, fully human or humanized antibodies retaining dengue virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: October 27, 2009Date of Patent: December 25, 2012Assignee: The United States of America as represented by the Secretary, Department of Health & Human ServicesInventors: Ching-Juh Lai, Robert H. Purcell
-
Publication number: 20120321614Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit c-Met. The invention also relates to human anti-c-Met antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-c-Met antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-c-Met antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-c-Met antibodies.Type: ApplicationFiled: April 24, 2012Publication date: December 20, 2012Applicants: Pfizer, Inc., Amgen Fremont Inc.Inventors: Neil R. Michaud, Shama Kajiji, Gary Borzillo, Vahe Bedian, Kevin Coleman, Larry L. Green, Xiao-Chi Jia
-
Publication number: 20120321617Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as the 1L-10 receptor ? (IL-I10Ra) and is not capable of binding IL-10 when the IL-10 is bound to the IL-10 receptor; and (ii) binds to IL-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibody or fragment thereof.Type: ApplicationFiled: November 30, 2010Publication date: December 20, 2012Applicant: BIOTEST AGInventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth
-
Publication number: 20120322975Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: ApplicationFiled: July 2, 2012Publication date: December 20, 2012Applicant: Genentech, Inc.Inventors: Michael S. C. Fung, William N.C. Sun, Cecily R. Y. Sun
-
Publication number: 20120321618Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (Th-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof.Type: ApplicationFiled: November 30, 2010Publication date: December 20, 2012Applicant: BIOTEST AGInventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth, Andrea Wartenberg-Demand, Marcus Gutscher, Judith Wessels-Kranz
-
Publication number: 20120321636Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.Type: ApplicationFiled: August 22, 2012Publication date: December 20, 2012Applicant: UCB Manufacturing, Inc.Inventors: David G. Winkler, Jiye Shi, John Latham
-
Publication number: 20120321589Abstract: Disclosed herein are polypeptides which comprise all or part of an antibody linked to all or part of a cytokine. The cytokine sequences of the polypeptides have a modified heparin binding region which disrupts, inhibits, or reduces the ability of the cytokine to bind a heparin compound as compared to a corresponding cytokine having an unmodified heparin binding region. Also disclosed are methods of treating cancer, inducing cell proliferation, and reducing the non-specific binding and/or non-specific localization of the polypeptides.Type: ApplicationFiled: March 11, 2011Publication date: December 20, 2012Inventors: Manuel L. Penichet, Rosendo Luria-Perez, Gustavo Helguera
-
Publication number: 20120315275Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.Type: ApplicationFiled: August 20, 2012Publication date: December 13, 2012Inventors: Peter Whitefeld, David Zahra, Charles Mackay
-
Patent number: 8318472Abstract: An optimized nucleic acid sequence encoding the immunoconjugate VB4-845 is disclosed. Modifications to the original VB4-845 nucleic acid sequence include optimization of the sequences encoding the VH region, VL region, linkers and pseudomonas exotoxin A. The modifications improved the yield of VB4-845 in an Escherichia coli expression system.Type: GrantFiled: September 26, 2008Date of Patent: November 27, 2012Assignee: Viventia Biotechnologies Inc.Inventors: Jeannick Cizeau, Glen MacDonald, Arjune Premsukh
-
Publication number: 20120294861Abstract: The invention provides FGFR1 agonists, including agonistic anti-FGFR1 antibodies, and methods of using the same.Type: ApplicationFiled: May 15, 2012Publication date: November 22, 2012Applicant: Genentech, Inc.Inventors: Junichiro Sonoda, Yan Wu
-
Publication number: 20120295310Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.Type: ApplicationFiled: June 21, 2012Publication date: November 22, 2012Inventors: Katherine E. Lewis, Scott R. Presnell, James W. West, Robert Mabry, Brent Meengs, Steven D. Levin
-
Publication number: 20120294857Abstract: The present invention embraces a bi-specific fusion protein composed of an effector cell-specific antibody-variable region fragment operably linked to at least a portion of a natural killer cell receptor. Methods for using the fusion protein in the treatment of cancer and pathogenic infections are also provided.Type: ApplicationFiled: January 7, 2011Publication date: November 22, 2012Applicant: Trustees of Dartmouth CollegeInventors: Charles L. Sentman, Tong Zhang
-
Patent number: 8313747Abstract: An antikine antibody binds to two, three, four, five or more CC chemokines, such as RANTES/CCL5, MIP-1?/CCL3, MIP-1?/CCL4, or MCP-1/CCL2. Methods for affinity maturation and humanization of antikine antibodies as well as the production of hybridoma cell lines producing antikine antibodies by sequential immunization are also disclosed.Type: GrantFiled: August 27, 2010Date of Patent: November 20, 2012Assignee: VLST CorporationInventors: Dan Allison, Carol Raport
-
Publication number: 20120288494Abstract: The present invention provides antibodies, and antigen-binding portions thereof, that bind to epitopes comprising at least one amino acid residues from residues 1-197 of the p40 subunit of IL-12 and/or IL-23. The invention further provides nucleic acids encoding the antibodies, compositions, vectors and host cells comprising the antibodies, and methods of making and using the same.Type: ApplicationFiled: January 6, 2012Publication date: November 15, 2012Applicant: Abbott LaboratoriesInventors: David W. Borhani, Ramkrishna Sadhukhan, Susan E. Lacy, Holly H. Soutter
-
Publication number: 20120288502Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) antibodies having improved potency and breadth.Type: ApplicationFiled: July 25, 2012Publication date: November 15, 2012Inventors: Ron Diskin, Pamela J. Bjorkman, Michel Nussenzweig, Johannes Scheid
-
Publication number: 20120282254Abstract: Antigen binding proteins which bind to human IL-7 receptor (CD127) are provided. The antigen binding proteins are typically antibodies, and are useful in the treatment of diseases or disorders in humans, particularly autoimmune diseases such as multiple sclerosis.Type: ApplicationFiled: January 26, 2011Publication date: November 8, 2012Inventors: Ian Kirby, Alexander H. Taylor, Thomas Matthew Webb, Yu Xue
-
Publication number: 20120282637Abstract: The present invention relates to a polypeptide or polypeptide complex comprising at least the two amino acid sequences arranged to allow for specific binding to the “receptor for advanced glycation endproducts” (RAGE), one or more nucleic acid(s) coding for the polypeptide or polypeptide complex, a cell producing an antibody against RAGE, a pharmaceutical composition comprising at least one polypeptide or nucleic as defined above, optionally for treating a RAGE-related disease or disorder and a method of diagnosing a RAGE-related disease or disorder.Type: ApplicationFiled: October 8, 2010Publication date: November 8, 2012Applicant: SANOFIInventors: Jochen Huber, Francis Blanche, Tarik Dabdoubi, Fabienne Soubrier, Ingo Focken, Jochen Kruip, Kathrin Heermeier, Christian Lange
-
Publication number: 20120282253Abstract: The methods and compositions provided herein relate generally to IL-10 specific antibodies and uses thereof. More specifically, compositions of humanized IL-10 specific antibodies and methods to use such antibodies in modulating the biological activity of IL-10, particularly in autoimmune disorders and pathogen-mediated immunopathology.Type: ApplicationFiled: July 19, 2012Publication date: November 8, 2012Applicant: Schering CorporationInventor: Leonard G. Presta
-
Publication number: 20120277412Abstract: A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.Type: ApplicationFiled: July 12, 2012Publication date: November 1, 2012Inventors: Shoji FURUSAKO, Kazuyuki Nakayama, Yoshitaka Hosaka, Tetsushi Kawahara, Masaki Nakamura, Takashi Takeuchi
-
Publication number: 20120275997Abstract: The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those anitbodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.Type: ApplicationFiled: October 8, 2010Publication date: November 1, 2012Inventor: Jean-François Haeuw
-
Patent number: 8298836Abstract: Disclosed is an isolated polynucleotide encoding a modified Fab' antibody, which includes an Fd chain and an L chain with the Fd chain including a CH1 region and the L chain including a CL region, wherein the modified Fab' antibody further includes a cysteine for binding to a fluorescent dye, and the polynucleotide includes an Fd chain coding region and an L chain coding region linked therebetween in a manner that will allow expression of the modified Fab' antibody. Also disclosed are an expression vector containin the isolated polynucleotide, an isolated transformed host cell containing the expression vector, and a cell culture including the transformed host cell.Type: GrantFiled: November 2, 2004Date of Patent: October 30, 2012Assignee: Hamamatsu Photonics K.K.Inventors: Sunao Hisada, Yukiko Ito, Hiroyuki Matsumoto, Kiyohito Shimura, Kenichi Kasai
-
Publication number: 20120269807Abstract: Provided herein are compositions and related methods for delivering an IgG-decoy receptor to the CNS. The methods include systemic administration of a bifunctional decoy receptor-BBB receptor antibody fusion antibody comprising a receptor extracellular domain (ECD) covalently linked to an antibody to a receptor expressed on the surface of the blood-brain barrier (BBB receptor). In some embodiments, the compositions described herein are administered to treat a subject suffering from a CNS condition.Type: ApplicationFiled: March 18, 2010Publication date: October 25, 2012Inventors: William M. Pardridge, Ruben J. Boado
-
Publication number: 20120269765Abstract: Polypeptides, including non-naturally occurring and recombinantly modified polypeptides related to the p19 subunit of IL-23, methods of making such molecules and methods of using such molecules as therapeutic, prophylactic and diagnostic agents are provided.Type: ApplicationFiled: July 26, 2010Publication date: October 25, 2012Inventors: K. Christopher Garcia, Patrick Lupardus, Sashank K. Reddy, Gregory J. Sieczkiewicz
-
Patent number: 8293480Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.Type: GrantFiled: September 26, 2008Date of Patent: October 23, 2012Assignee: Genpharm InternationalInventors: Nils Lonberg, Robert M. Kay
-
Publication number: 20120263722Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.Type: ApplicationFiled: November 3, 2011Publication date: October 18, 2012Inventors: Tariq Ghayur, Junjian Liu, Peter C. Isakson
-
Publication number: 20120258495Abstract: Compositions and methods are disclosed for generating immunoglobulin structural diversity in vitro, and in particular, for reducing biases in V region and J segment gene utilization, and for generating immunoglobulin V-D-J recombination events in a manner that does not require D-J recombination to precede V-DJ recombination. Selection of advantageous combinations of immunoglobulin gene elements, including introduction of artificial diversity (D) segment genes and optimization of recombination signal sequence (RSS) efficiency, are disclosed.Type: ApplicationFiled: August 8, 2011Publication date: October 11, 2012Inventors: Michael Gallo, Jaspal Singh Kang, Craig Robin Pigott
-
Publication number: 20120258108Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.Type: ApplicationFiled: November 1, 2011Publication date: October 11, 2012Inventors: Tariq Ghayur, Junjian Liu, Jijie Gu, Maria C. Harris
-
Patent number: RE43823Abstract: Compositions are provided that comprise antibody against coreceptors for human immunodeficiency virus such as CCR5 and CXCR4. In particular, monoclonal human antibodies against human CCR5 are provided that bind to CCR5 with high affinity and are capable of inhibiting HIV infection at low concentrations. The antibodies can be used as prophylactics or therapeutics to prevent and treat HIV infection, for screening drugs, and for diagnosing diseases or conditions associated with interactions with HIV coreceptors.Type: GrantFiled: November 18, 2011Date of Patent: November 20, 2012Assignee: Genetastix CorporationInventors: Shaobing Hua, Michelle Haynes Pauling, Li Zhu
-
Patent number: RE44024Abstract: This invention provides an isolated polynucleotide encoding an ECA1 polypeptide. Also provided is the isolated ECA1 polypeptide Further provided is an antibody that specifically recognizes and binds the ECA1 polypeptide or an epitope thereof. The polynucleotides, antibodies and/or polypeptides of this invention may be components of compositions, host cells and/or gene delivery vehicles, where appropriate. In one aspect, the host cell will produce recombinant ECA1, which is further defined herein. In another aspect, the host cell is an antigen presenting cell such as a dendritic cell, and it will display an antigenic portion of the ECA1 polypeptide on its surface. The polypeptides, proteins and compositions of this invention are useful to aid in the diagnosis of a neoplastic condition of a cell of endometrioid origin.Type: GrantFiled: May 13, 2010Date of Patent: February 19, 2013Assignee: The University of Southern CaliforniaInventors: Michael F. Press, Bahman Saffari